A DEFINITY® Echo
Diagnostic Advantage in Suboptimal Echoes

In a large, retrospective observational Premier Perspective™ Database study with over 1,000,000 critically ill patients:\(^1\)

A 32% reduction in the risk of mortality was seen after DEFINITY® versus non-contrast echocardiography over the initial 48 hours.

In a large prospective study of consecutive patients with technically difficult studies (n=632):\(^2\)

- 33% of patients avoided further diagnostic procedures due to improved LV function assessment (p<0.0001)
- This resulted in a cost savings to the healthcare system estimated at $122/patient

For more information on training or implementation please contact Lantheus Medical Imaging via your representative or at: Lantheus_at_your_service@lantheus.com

Lantheus Medical Imaging – Your partner in CEUS

Lantheus Medical Imaging has been working with leaders in the echocardiography community to provide product knowledge and training support in the pursuit of optimizing patient diagnosis.

NOW reimbursed in Ontario\(^3\)

Please refer to the product monograph (available upon request from Lantheus MI Canada Inc.) for complete prescribing information including information contained in the BOXED WARNING.
INDICATIONS

Echocardiography

DEFINITY (perflutren injectable suspension) is indicated for contrast-enhanced ultrasound imaging of cardiac structures (ventricular chambers and endocardial borders) and function (regional wall motion) in adult patients with suboptimal echocardiograms.

CONTRAINDICATIONS

Do not administer DEFINITY® (perflutren injectable suspension) to patients with known:

- Hypersensitivity to DEFINITY® or its components (See WARNINGS - Hypersensitivity Reactions and ADVERSE REACTIONS - Post Market Adverse Drug Reactions).
- Right-to-left, bi-directional, or transient right-to-left cardiac shunts (see WARNINGS - Systemic Embolization).

DEFINITY® should not be injected by direct intra-arterial injection (see WARNINGS - Systemic Embolization).

Gas contrast agents, for use in diagnostic ultrasound examinations, should not be administered within 24 hours prior to extracorporeal shock wave lithotripsy.

WARNINGS

WARNING: Serious Cardiopulmonary Reactions

Serious cardiopulmonary reactions, including fatalities, have occurred during or following DEFINITY® administration. The risk for these reactions may be increased among patients with unstable cardiopulmonary conditions (acute myocardial infarction, acute coronary artery syndromes, worsening or unstable congestive heart failure, serious ventricular arrhythmias or respiratory failure, including patients receiving mechanical ventilation). In these patients, observe closely for at least 30 minutes after DEFINITY® administration.

DEFINITY® should only be administered to such patients after a careful risk/benefit assessment. Assess all patients for the presence of any conditions that precludes DEFINITY® administration (see CONTRAINDICATIONS).

In the absence of these underlying conditions, observe patients closely during and following DEFINITY® administration for at least 30 minutes for potential serious reactions.

Always have cardiopulmonary resuscitation equipment and trained personnel readily available prior to DEFINITY® administration and observe all patients for acute reactions.

Please refer to the product monograph for complete prescribing information including information contained in the boxed warning.

REFERENCES:

1. DEFINITY® [Product Monograph]. Lantheus Medical Imaging, Montreal, QC October 2011